The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization.
Topical application of antigen induces antigen-specific humoral and cellular immune responses. In this study we examined whether expansion of dendritic cells (DC) by Flt3 ligand (Flt3L) treatment influences the induction of immune responses following transcutaneous immunization. Mice were treated intraperitoneally with Flt3L or phosphate-buffered saline (PBS) and immunized transcutaneously with hen egg lysozyme (HEL). Flt3L-treated mice developed lower HEL-specific cellular and humoral immune responses than PBS-treated mice. However, in the presence of cholera toxin (CT), a potent adjuvant for mucosal and transcutaneous immunization, Flt3L-treated mice developed significantly higher cellular and humoral immune responses to HEL when compared to PBS-treated mice. We assessed whether the immunomodulatory effects of CT were a result of activation of epidermal dendritic cells (Langerhans' cells; LC). Our results indicate that within 8-12 hr of topical application of CT, epidermal LC cells lose their dendritic morphology and become rounder in appearance. In addition, we observed enhanced expression of major histocompatibility complex (MHC) class II, and of adhesion molecules CD11c and intracellular adhesion molecule-1 (ICAM-1). Our observations support the concept that the state of activation of DC in the skin is central to the regulation of immune responses. This information is relevant to the design of effective transcutaneous vaccination strategies.
Baca-Estrada
Maria E
ME
Veterinary Infectious Disease Organization, Department of Animal and Poultry Science and College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada. mbacaest@hc-sc.gc.ca
Ewen
Catherine
C
Mahony
Donna
D
Babiuk
Lorne A
LA
Wilkie
Darryl
D
Foldvari
Marianna
M
D000276:Adjuvants, Immunologic; D000279:Administration, Cutaneous; D000818:Animals; D039521:CD11c Antigen / Q000378:metabolism; D002772:Cholera Toxin / Q000276:immunology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D007114:Immunization / Q000379:methods*; D007074:Immunoglobulin G / Q000096:biosynthesis; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007801:Langerhans Cells / Q000276:immunology*; D008024:Ligands; D008565:Membrane Proteins / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009113:Muramidase / Q000276:immunology
D000276:Adjuvants, Immunologic; D039521:CD11c Antigen; D000949:Histocompatibility Antigens Class II; D007074:Immunoglobulin G; D008024:Ligands; D008565:Membrane Proteins; C084881:flt3 ligand protein; D018799:Intercellular Adhesion Molecule-1; D015847:Interleukin-4; D007371:Interferon-gamma; D002772:Cholera Toxin; C421864:hen egg lysozyme; D009113:Muramidase